Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects

Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue

(2015) Michael W. Dunne et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A thorough QT study with dalbavancin: A novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections

(2015) Michael W. Dunne et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12–17 Years of Age

(2015) John S. Bradley et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection

(2014) Helen W. Boucher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dalbavancin: Quantification in human plasma and urine by a new improved high performance liquid chromatography–tandem mass spectrometry method

(2011) Tanja Alebic-Kolbah et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Pharmacokinetics of Dalbavancin in Patients With Renal or Hepatic Impairment

(2009) Thomas Marbury et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetic-Pharmacodynamic Modeling of Dalbavancin, a Novel Glycopeptide Antibiotic

(2008) James A. Dowell et al.   JOURNAL OF CLINICAL PHARMACOLOGY